San Mateo, Calif., and Cambridge, Mass., January 8, 2020 – Kronos Bio, Inc., dedicated to the development of first-in-class therapies that modulate historically undruggable targets, announced today that it has appointed Wes Trotter, Ph.D., as Vice President, Chemistry. In this position, Dr. Trotter will oversee medicinal chemistry efforts across the company’s pharmaceutical modulatory and targeted protein degrader programs. Dr. Trotter is based in Kronos’ Cambridge office.
“We are excited to have Wes join our R&D leadership team given his 20 years of medicinal chemistry experience at Merck, where he led discovery and preclinical development teams spanning several therapeutic areas including oncology. In that role he invented multiple novel small molecules and advanced them to preclinical and clinical milestones,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “With Wes’ significant experience taking on complex targets in oncology, he will be a valuable addition to Kronos as we focus on enhancing our discovery pipeline.”
Dr. Trotter began his career in medicinal chemistry at Merck & Co. in 1999 and has held positions of increasing leadership. Most recently, he was Director, Discovery Chemistry, where he led a cross-functional, cross-site immuno-oncology drug discovery program that delivered novel STING agonists into ongoing Phase 1 studies. He previously led additional cross-functional immunology and oncology teams that invented preclinical and clinical candidate molecules. Dr. Trotter has published extensively in peer reviewed-journals and has been issued 25 U.S. patents.
“I was immediately impressed by Kronos’ experienced management team and internal discovery pipeline of preclinical oncology programs, which resulted from hits identified by its novel Small Molecule Microarray platform,” said Dr. Trotter. “After two decades at Merck, I look forward to bringing my experience to Kronos and working closely with Norbert, a fellow organic chemist, and the talented R&D team to discover and develop innovative therapies against some of the most challenging targets in cancer research.”
Dr. Trotter received a B.S. in chemistry from the University of North Carolina at Chapel Hill, an M.Phil. in bio-organic chemistry from the University of Cambridge, where he was a Churchill Scholar, and a Ph.D. in organic chemistry from Harvard University.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.
# # #